Piramal Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Piramal Pharma announced that the 5th Annual General Meeting(AGM) of the company will be held on 30 July 2025.

Powered by Capital Market - Live News

Piramal Pharma announced that the US FDA conducted a general GMP (Good Manufacturing Practices) Inspection of Piramal Pharma's facility at Aurora, Canada from 26 May 2025 to 30 May 2025.

The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.

Powered by Capital Market - Live News

According to a regulatory filing, the inspection was carried out from 26 May 2025 to 30 May 2025. At the conclusion of the inspection, the USFDA issued a zero-observation report in Form 483 and granted a no action indicated (NAI) designation.

The company remains dedicated to maintaining the highest standards of compliance.

Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products.

The company?s consolidated net profit jumped 51.6% to Rs 153.50 crore on 7.9% rise in revenue from operations to Rs 2,754.07 crore in Q4 FY25 over Q4 FY24.

Shares of Piramal Pharma rose 0.36% to Rs 207.05 on the BSE.

Powered by Capital Market - Live News

Piramal Pharma has allotted 35 lakh equity shares under ESOP on 21 May 2025.

Consequent to this allotment, the paid-up share capital of the Company stands increased from to Rs. 1329,24,81,300 (consisting of 132,92,48,130 equity shares of face value of Rs. 10/- each).

Powered by Capital Market - Live News